Regeneron to Report Third Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on October 24, 2012

TARRYTOWN, N.Y.,Oct. 10, 2012/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)today announced that it will report its third quarter 2012 financial and operating results onWednesday, October 24, 2012, before the U.S. financial markets open.  The Company will host a conference call and simultaneous webcast at8:30 AM ESTthat day.

Conference Call InformationTo access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International).  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website atwww.regeneron.com.  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets three products inthe United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use; ZALTRAP is co-commercialized with Sanofi.  Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site atwww.regeneron.com.